Autofluorescence Detection of Bronchial Tumors With the D-Light/AF by Häußinger, K. et al.
Diagnostic and Therapeutic Endoscopy, Vol. 5, pp. 105-112
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1999 OPA (Overseas Publishers Association) N.V.
Published by license under
the Harwood Academic Publishers imprint,
part of The Gordon and Breach Publishing Group.
Printed in Singapore.
Autofluorescence Detection of Bronchial Tumors
with the D-Light]AF
K. HUI3INGER a’*, F. STANZEL a, R.M. HUBERb, j. PICHLER and H. STEPP
aClinic for Pneumology, Fachklinik Mfinchen Gauting, Robert-Koch-Allee 2, D-82131 Gauting, Germany;
bDivision of Pneumology, Department of Medicine, Klinikum Innenstadt, University of Munich, Germany;
Laser Research Institute, Department of Urology, University of Munich, Germany
We present a newly developed diagnostic system combining a conventional light source (white
lightmode and two different fluorescence excitation modes), a bronchoscope and optionally a
highly sensitive camera (Baumgartner et al., Photochem. Photobioi. 1987; 46(5): 759-763).
Routine diagnostics can be performed with the autofluorescence bronchoscopy (AFB) and the
white light bronchoscopy (WLB) in one diagnostic procedure. The image is visible directly
with the naked eye. The system was evaluated in a pilot study including 60 patients. Two
hundred and sixty-four biopsies were taken to detect premalignant and malignant findings
(Stanzel et al., Contribution to 10th World Congress for Bronchology, June 1998). The
sensitivity of the combination of WLB and AFB was 2.8 times higher than that of the
conventionalWLB. The specificity decreased from94% (WLB) to89% (WLB+ AFB). The
results of this preliminary pilot study are being confirmed in a multicenter study, which will
begin at seven European centers.
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INTRODUCTION
Invasive bronchogenic lung cancer represents the
final stage of a long sequence of cellular and tissue
alterations [3]. Animal experiments have shown
hyperplasia and metaplasia of the bronchial
mucosa to be a gradual development up to
dysplasia, carcinoma in situ (CIS) and invasive
carcinoma. Premalignancies are clearly defined by
histomorphological criteria by WHO: Dysplasia is
considered as premalignancy and is characterized by
cellular atypia in metaplastic epithelial tissue.
Carcinoma in situ is defined by nuclear and cellular
atypia in partially abolished and irregular cell
layers. In bronchogenic carcinoma the basement
membrane is destroyed and the stroma is infiltrated.
Endoscopy for detection ofearly lung cancermay
be helpful for two reasons: Firstly carcinogenesis is a
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slow process evolving over years, and is estimated to
take 3-4 years for dysplasia and approximately a
further six months for CIS [4,5]. Secondly about
50-60% of all lung cancers, especially squamous
cell carcinomas, develop in the central airways.
These cancers can be detected by endoscopy, but
are generally roentgenographically occult [6].
The main problem for conventional broncho-
scopy is its low sensitivity and specificity for
detection of early malignant changes [7]. Premalig-
nant lesions usually are small and only some cell
layers thick [8]. Their endoscopic signs therefore are
very subtle and can be missed even by experienced
bronchoscopists. To improve the sensitivity and
specificity of conventional endoscopy, diagnostic
fluorescence procedures were developed [9]. The
principles of these procedures are based on a
difference in fluorescence between normal tissue
and premalignant and malignant tissue. This differ-
ence can be visualized by introducing stimulating
light of a special wavelength (380-460 nm) [10].
Two basic methods are available:
the detection of the specific autofluorescence of
tumor tissue and normal tissue [11],
the application of photosensitive drugs, which
selectively accumulate in tumor tissue and cause a
specific drug induced fluorescence [12] (contribu-
tion by Dr. Huber et al.).
In the following we will describe the detection of
the specific autofluorescence by a special technical
system, developed by the Karl Storz company
(Tuttlingen, Germany) in collaboration with the
Laserforschfingslabor (LFL) of the University of
Munich, Germany.
on were replaced by 5-aminolevulinic acid (Medac
company, Hamburg) [14], the krypton laser was
replaced by a conventional xenon light source
emitting a broadbanded excitation light (D-Light,
Karl Storz company, Germany) [15]. A detection
filter on the ocular of the bronchoscope allowed
observation of the flourescence light with the naked
eye. With this method autofluorescence of low
intensity could be detected even in patients without
prior application of5-aminolevulinic acid [16]. Both
the autofluorescence and the contrast between
tumor and normal tissue were very low. To increase
the contrast and the light intensity of the D-Light
system, the detection filters and the light guidance
devices of the bronchoscope were optimized. The
detection filters were modified allowing only the
passage of a small part of the blue excitation light.
After modification we obtained a higher color
contrast, a higher light intensity and a more 3-D-
image. Finally the application of photosensitive
drugs became unnecessary.
The system in the actual version can be used with
flexible as well as with rigid bronchoscopes. The
findings are documented with a highly sensitive
integratingcamerawhich isputdirectlyon the ocular
of the bronchoscope. The technical details of the
present system are explained in the contribution by
Dr. M. Leonhard. Optionally and experimentally
spectral detection of the specific autoflourescence
by a beam splitter can be added [17]. Figure shows
MATERIALS AND METHODS
Technical Development, Final Equipment
First attempts with the fluorescence detection were
accomplished with hematoporphyrin derivatives
as marker substance and a krypton laser for
excitation [13]. Hematoporphyrin derivatives later FIGURE Technical setup.LUNG CANCER DETECTION BY D-LIGHT/AF 107
the complete system D-Light/AF with bron-
choscope and camera as well as the optional
spectrometer.
The color of the normal mucosa is dominated by
a green fluorescence, while malignant tissues are
indicated by changes in the color, relief and fine
structure of the mucosal surface.
Clinical Study
The system D-Light/AF was tested in a pilot study
including 60 patients (44 males, 16 females) with
increased risk for developing bronchial carcinoma.
Overall 264 biopsies were taken. According to the
criteria ofthe International Association of Study of
Lung Cancer (IASLC) [18] patients who met the
following criteria were included:
classification:
1. normal appearance, unsuspicious;
2. non-specific changes:
e.g. scars, granulomas, swelling, anatomical
anomalies,
inflammation (acute chronic bronchitis), con-
fessed (preceeding) location of biopsies;
3. suspicion of malignant changes;
4. visible tumor (e.g. exophyt).
The mean age of the patients investigated was
62.2 years (37-80 years). Forty-nine patients under-
went bronchoscopy because of radiological or clini-
cal suspicion for malignancy, 4 patients had positive
findings in cytology, 11 patients had undergone
surgical treatment due to bronchial carcinoma.
Radiological or clinical suspicion of carcinoma;
Postoperative care (resected bronchial
carcinoma);
Positive cytological findings;
Previous positive findings of dysplasia/CIS;
Known bronchial carcinoma (e.g. staging);
Smoker older than 40 years and evidence of
COPD and/or occupational exposure.
Bronchoscopy was performed with local anesthesia
with flexible instruments or with general anesthesia
with rigid tubes in combination with flexible
bronchoscopes. The detection of autofluorescence
was performed only by flexible bronchoscopes. In
some individual cases autofluorescence detection in
the trachea and the main stem bronchii was
performed by rigid optical devices to obtain a better
documentation.
The investigation first started with white light
mode switching over to blue light mode for the
detection of the specific autofluorescence. Biopsies
were taken from all suspicious areas detected
either by WLB and/or AFB. Additionally in every
patient two random biopsies were taken from
normal bronchial tissue. The biopsies were des-
cribed in WFB as well as in AFB by the following
RESULTS
Mean time for overall bronchoscopy was 25 min on
average. Additional AFB lasted 7 min on average.
For the detection rate of dysplasia and carcinoma
in situ we found a clear increase of sensitivity and
for normal tissue a minor decrease of specificity:
We found 5 cases of mild dysplasia (1 in WLB, 3 in
AFB, in WLB + AFB), 6 cases of moderate to
severe dysplasia (3 inAFB, inWLB, 2 non-specific
in WLB+AFB), case of carcinoma in situ
(suspicious in WLB + AFB) and 36 tumors (1 in
WLB, in AFB, 28 in AFB / WLB, 6 non-specific
in WLB and AFB). The prevalence for moderate
dysplasia, severe dysplasia and CIS was 7% for
WLB alone and 12% forWLB +AFB (the unspec-
ific findings are included) (see Table I). The number
of false positive findings of the 216 biopsies taken
from normal tissue is small (5 in WLB, 12 in AFB, 8
in AFB + WLB).
The positive predictive value indicates that most
of the biopsies taken from suspicious areas were
confirmed histologically, i.e. autofluorescence in-
vestigation caused an additional expense which was
adequate to the final positive results. The high
negative predictive value shows that only few108 K. H,/i,UI3INGER et al.
TABLE Pilotstudy with 60 patients and 264 biopsies
Sensitivity PPV
Dysplasia/CIS Tumors Dysplasia CIS/Tumors
NPV Specificity
Dysplasia CIS/Tumors
White light 33% 81% 72%
White light/ Autofluorescence 83% 83% 63%
Relative factor 2.80 1.03
93% 94%
96% 89%
biopsies were false negatives which had beenjudged
to be unspecific.
The specificity was very high even if autofluores-
cence and white lightendoscopy were combined. We
found the same amount of false positive biopsies
characterizing inflamations or metaplasias (3 in
WLB, 3 inAFB, 4 inAFB + WLB), scars or necrotic
tissue (4 in AFB +WLB) in autofluorescence mode
as well as in white light mode. In the combination
WLB /AFB the amount of false positive results
increased only slightly.
Figure 2 shows the middle lobe carina of a heavy
smoker, which appears quite normal under WLB,
while the fluorescence image shows a circumscript
brown area, which indicates a histologically proven
carcinoma in situ.
Figure 3 shows the left upper lobe carina of a
patient who was investigated bronchoscopically
because of a positive sputum cytology and negative
X-ray image. White light bronchoscopy shows
slight irregularity and fine roughening of the
mucosa, which can be missed easily. Autofluores-
cence findings are characterized as marked brown-
ish/bluish discoloration, indicating the transitional
zone to the healthy tissue. Histologically we found
microinvasive carcinoma within a larger area of
carcinoma in situ.
Figure 4 shows the middle lobe bronchus of a
heavy smoker who had undergone both lobectomy
of left lower lobe and right upper lobe because of
synchronous bronchial carcinomas. Years later we
found a mild dysplasia by routine bronchoscopy
in the dorsal wall of the middle lobe bronchus.
The finding is marked only by a bluish color in
the autofluorescence image. White light findings
were normal.
FIGURE 2 Carcinoma in situ located at the middle lobe
carina: (a) white light mode, (b) autofluorescence mode (flex-
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FIGURE 3 Microinvasive carcinoma in situ with a larger
area of CIS: (a) white light mode, (b) autofluorescence mode
(rigid bronchoscope).
FIGURE 4 Mild dysplasia in the dorsal wall of the middle
lobe bronchus: (a) white light mode, (b) autofluorescence
mode (flexible bronchoscope).
Figure 5 shows an example of an autofluores-
cence spectrum taken from an area of severe
dysplasia at the upper lobe carina and from normal
tissue after excitation with blue light (380-460 nm).
Both spectra are corrected to eliminate distance
dependency [19]. Excitation of tumor tissue results
in a strongly reduced intensity of the spectrum in
the range between 500-600 nm. There is no differ-
ence between tumor and normal tissue for wave-
lengths above 650 nm [20].110 K. HUBINGER et al.
FIGURE 5 Spectrum of normal (N) and neoplastic (T)
epithelium.
DISCUSSION
The fluorescence system ofthe Karl Storz Company
is based on the different fluorescence emissions
of normal tissue and tumor tissue, either sponta-
neously as autofluorescence light or as drug induced
fluorescence by selective accumulation of exoge-
neous applicated photosensitizers in the tumor
tissue. This newly developed system can be used
for both fluorescence diagnostic procedures. In the
following only specific problems of autofluores-
cence diagnostic procedures are discussed.
The different concentrations of fluorophors in
mucosal structures cause a characteristic image of
color and a specific 3-D-image in the relief of
mucosal surfaces. The color of the normal mucosa
is dominated by a green fluorescence predominantly
originating from connective tissue structures, which
is interrupted by some darker, more brownish
looking structures according to anatomy and mor-
phology of smooth muscles within the mucosal
membrane. A special 3-D-image is created by the
tramline phenomenon of the pars membranacea.
The normal mucosa of carinas is characterized by a
homogeneous area of green color, while malignant
tissue is indicated by circumscript areas ofbrownish
or bluish discoloration within the green area of
normal tissue. Other signs of malignancy are
disturbance and/or dissolution of the normal
anatomical structure and its specific color varia-
tions. The interpretation of different phenomena
requires profound experience in endoscopy and a
continuous feedback ofanatomical and histological
results.
To obtain endoscopical visualization with auto-
fluorescence, different technical systems were devel-
oped. The first, called LIFE-system (laser induced
fluorescence endoscopy), was developed by the
Xillix corporation and was based on a helium-
cadmium laser and an image intensifier camera. The
result is an indirect electronic pseudo image. The
components of the newly developed Karl Storz
system, presented by M. Leonhard in detail are
more convenient. The system is based on a modified
xenon light source, on a filter in the ocular of
the bronchoscope and an optional integrating
camera which can be attached easily. The system
allows the direct investigation by the naked eye
and a quick and simple change between white
light and autofluorescence mode by a foot-
switch. Light intensity and quality of the image of
the system are excellent, and allow an exclu-
sive bronchoscopical orientation and investigation
under autofluorescence guidance.
All systems presented as part of this monograph
aim at the early recognition ofpremalignant and/or
early malignant changes in the bronchial mucosa.
More than 50% of these changes in the central
airways [4] are achievablwith the flexible broncho’-
scope. The carcinogenesis lasts several years. Based
on an investigation of section specimens of com-
plete lungs Auerbach and Saccomano found a
prevalence of 4.3% and 11.4% in slight and heavy
smokers respectively [4,21,22]. Of all patients dying
from bronchial carcinoma 15% had synchronous
carcinomas. In patients with radiological occult
bronchial carcinoma CIS was found in 20%, micro-
invasive carcinomas were found in 41% [4,5].
These favourable preconditions offer a chance
of screening methods and endoscopic therapy.
To detect these premalignant and malignant
changes various available autofluorescence sys-
tems were tested in studies. Up to now, the only
large studies published have been about the Xillix

































FIGURE 6 Concept for a two-arm multicenter study to evaluate the disgnostic effort of the additional fluorescence detection in
contrast to a normal white light bronchoscopy.
In the British Columbia Cancer Agency Study
the proportion of biopsy-proven moderate to
severe dysplasia or CIS detected by WLB alone
was 39%. With the addition of LIFE examination,
the detection rate increased to 84% (WLB / AFB),
whereas specificity decreased from 91% (WLB) to
86% (WLB /AFB) [23].
In the US multicenter study, sensitivity for
dysplasia and carcinoma in situ increased from 9%
byWLB to 57% by additional AFB (relative factor
6.3), specificity decreased from 90% to 66%. The
prevalence ofmoderate to severe dysplasia and CIS
was 14.6%, the overall prevalence of premalignant
and malignant findings including invasive tumors
was 20% [24].
In comparison to the above mentioned.4-11%
[4,21,22] the prevalence of 15% for dysplasia and
CIS published in the US study seems to be over-
estimated, especially considering the limitation of
endoscopy to the central airways.
An explanation for the high prevalence reported
could be that several biopsies were obtained from
widespread malignant areas. In addition, some
pathological findings might originate from the
periphery of visible tumors. These topographic
regions are not the areas of our interest. The pri-
mary aim ofAFB is to detect isolated premalignant
or malignant findings.
In comparison to the Canadian study the Karl
Storz AF-system yielded a similar finding rate. The
factor of 6.3 for additional AFB seems to be
inadequatly high in the US multicenter study and
is obviously caused by the low sensitivity forWLB of
only 9%. The results of the published studies are at
least problematic considering one further aspect:
The study design did not definitely exclude a mutual
influence in the endoscopical classification of the
findings obtained byWLB orWLB + AFB.
We have designed a two-armed randomized
multicenter study to evaluate AFB in general and
our Karl Storz System in particular (Fig. 6)
One group of patients is investigated exclusively
by white light and the second by a combination of
WLB / AFB. To avoid mutual influence between
the two methods it is planned to record biopsies in
the direct periphery of tumors separately. So we
hope to receive a realistic prevalence rate for isolated
dysplasia and CIS. Finally the pathological findings
should be related to biopsies and patients as well.
Following this procedure we expect to find a
lower rate ofpremalignant and malignant findings,
butwe hope to receive a realistic evaluation ofnewly
developed fluorescence devices for clinical use in
early cancer detection.
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